Evoke Pharma Inc. (NASDAQ: EVOK) dropped 3.17% after the company announced the commencement of more marketing initiatives focusing on introducing physician and patient experience programs for GIMOTI, its nasal spray of relief of acute and recurrent diabetic gastroparesis (DGP) symptoms.
Evoke launches GIMOTI experience program
The program will offer GIMOTI samples mainly to advance practice practitioners and targeted gastroenterologists. Most importantly, the program will expand GIMOTI awareness and trials for both patients and physicians to help them gain experience with the nasal spray and the non-oral treatment advantages.
Evoke CEO David Gonyer said, “We are pleased to announce the launch of the GIMOTI patient and physician experience program. This is an important opportunity to provide GIMOTI directly to physicians who haven’t prescribed GIMOTI and increase trial among patients with DGP who seek an alternative approach to traditional oral medications. We previously reported results from a recent market research study where gastroenterologists indicated a moderate-to-high level of concern about their patients’ ability to absorb oral medications, and estimated 20-40% of their patients with DGP may experience this difficulty.”
Gonyer added that 90% of targeted gastroenterologists have indicated that they plan to prescribe GIMOTI. He said that they are optimistic that the experience program will expand the network of patients and physicians familiar with GIMOTI. Equally, it will help ensure diabetic gastroparesis patients can access the novel treatment.
Evoke and EVERSANA conduct marketing study on GIMOTI
Recently the company and EVERSANA reported promising findings for a second GIMOTI market research study. The study sought to gather additional market insight into GIMOTI perception in the GI community and come back to the first study carried in December 2020.
EVERSANA is Evoke’s commercialization partner, and it conducted the GIMOTI Awareness Trial Usage Study to sensitize physicians about GIMOTI. The study comprises four sections, prescribing behavior, treating diabetic gastroparesis, treatment awareness, and more perspectives.
